Squarepoint Ops LLC Has $21.90 Million Position in AnaptysBio, Inc. $ANAB

Squarepoint Ops LLC boosted its position in AnaptysBio, Inc. (NASDAQ:ANAB) by 21.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 324,446 shares of the biotechnology company’s stock after buying an additional 56,743 shares during the quarter. Squarepoint Ops LLC owned approximately 1.10% of AnaptysBio worth $21,900,000 at the end of the most recent reporting period.

Several other institutional investors have also recently bought and sold shares of ANAB. Arizona State Retirement System grew its position in AnaptysBio by 13.5% in the 2nd quarter. Arizona State Retirement System now owns 4,363 shares of the biotechnology company’s stock worth $295,000 after purchasing an additional 518 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of AnaptysBio in the second quarter valued at about $1,164,000. California State Teachers Retirement System grew its position in AnaptysBio by 8,399.7% during the second quarter. California State Teachers Retirement System now owns 1,189,958 shares of the biotechnology company’s stock worth $80,322,000 after buying an additional 1,175,958 shares in the last quarter. Irenic Capital Management LP bought a new position in AnaptysBio during the second quarter valued at about $4,755,000. Finally, Ancora Advisors LLC acquired a new position in AnaptysBio in the 2nd quarter valued at approximately $338,000.

AnaptysBio Price Performance

ANAB opened at $56.60 on Wednesday. The firm has a 50 day simple moving average of $57.78 and a 200 day simple moving average of $59.27. AnaptysBio, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $72.36. The company has a market cap of $1.68 billion, a price-to-earnings ratio of -52.41 and a beta of 0.71.

Analyst Ratings Changes

Several brokerages recently commented on ANAB. Wolfe Research reaffirmed an “outperform” rating and issued a $78.00 target price on shares of AnaptysBio in a research report on Monday, August 31st. Wall Street Zen downgraded shares of AnaptysBio from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Leerink Partners set a $90.00 target price on shares of AnaptysBio in a research note on Friday, May 15th. Barclays increased their price target on shares of AnaptysBio from $63.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. Finally, TD Cowen cut their target price on AnaptysBio from $75.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, August 25th. Eleven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $79.85.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.